Future prospects in mRNA vaccine development.
COVID-19
cancer
mRNA vaccines
Journal
Biomedical materials (Bristol, England)
ISSN: 1748-605X
Titre abrégé: Biomed Mater
Pays: England
ID NLM: 101285195
Informations de publication
Date de publication:
17 08 2023
17 08 2023
Historique:
received:
23
05
2023
accepted:
02
08
2023
medline:
18
8
2023
pubmed:
17
8
2023
entrez:
17
8
2023
Statut:
epublish
Résumé
The recent advancements in messenger ribonucleic acid (mRNA) vaccine development have vastly enhanced their use as alternatives to conventional vaccines in the prevention of various infectious diseases and treatment of several types of cancers. This is mainly due to their remarkable ability to stimulate specific immune responses with minimal clinical side effects. This review gives a detailed overview of mRNA vaccines currently in use or at various stages of development, the recent advancements in mRNA vaccine development, and the challenges encountered in their development. Future perspectives on this technology are also discussed.
Identifiants
pubmed: 37589309
doi: 10.1088/1748-605X/aceceb
doi:
Substances chimiques
RNA, Messenger
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 IOP Publishing Ltd.